Table 3.
Post-diagnostic use of warfarin compared to anticoagulant non-users and seperately to users of other types of anticoagulants stratified by Defined Daily Doses (DDD), duration and intensity of usage
| n of deaths | Age-adjusted | Multivariable-adjusted | 1-year lag-time | 2-year lag-time | 3-year lag-time | |
|---|---|---|---|---|---|---|
| Warfarin compared to non-users | ||||||
| None | 509 | Ref | Ref | Ref | Ref | Ref |
| Any | 121 | 1.46 (1.12-1.90) | 1.47 (1.13-1.93) | 1.12 (0.85-1.48) | 1.12 (0.85-1.48) | 1.08 (0.83-1.41) |
| Amount of warfarin use | ||||||
| ≤200 DDD | 63 | 2.47 (1.84-3.31) | 2.50 (1.86-3.36) | 1.45 (1.04-2.02) | 1.34 (0.99-1.83) | 1.26 (0.94-1.70) |
| 200-667 DDD | 32 | 0.87 (0.53-1.42) | 0.88 (0.54-1.46) | 0.85 (0.52-1.41) | 0.76 (0.44-1.32) | 0.76 (0.43-1.36) |
| >667 DDD | 26 | 0.97 (0.56-1.68) | 1.02 (0.59-1.78) | 1.05 (0.60-1.83) | 1.15 (0.67-1.97) | 1.04 (0.58-1.85) |
| Duration of warfarin use | ||||||
| ≤1 year | 56 | 2.03 (1.47-2.81) | 2.04 (1.47-2.83) | 1.26 (0.89-1.78) | 1.25 (0.91-1.71) | 1.15 (0.85-1.57) |
| 2-4 years | 44 | 1.28 (0.88-1.87) | 1.30 (0.89-1.90) | 1.11 (0.73-1.69) | 0.87 (0.53-1.42) | 0.93 (0.56-1.54) |
| 5 or more years | 21 | 0.95 (0.49-1.85) | 1.05 (0.54-2.04) | 1.06 (0.56-1.99) | 1.37 (0.76-2.47) | 1.22 (0.66-2.26) |
| Intensity of warfarin use | ||||||
| ≤128 DDD/year | 45 | 1.92 (1.34-2.74) | 1.91 (1.34-2.74) | 1.31 (0.91-1.88) | 1.35 (0.98-1.86) | 1.21 (0.89-1.66) |
| 128-200 DDD/year | 51 | 1.74 (1.24-2.45) | 1.77 (1.25-2.50) | 1.13 (0.74-1.74) | 0.93 (0.57-1.51) | 0.94 (0.57-1.56) |
| >200 DDD/year | 25 | 0.73 (0.40-1.33) | 0.78 (0.43-1.43) | 0.99 (0.58-1.69) | 0.97 (0.56-1.69) | 0.99 (0.56-1.77) |
| Warfarin compared to other anticoagulant drugs | ||||||
| Non-warfarin anticoagulant users | 98 | Ref | Ref | Ref | Ref | Ref |
| Warfarin users | 121 | 1.13 (0.79-1.61) | 1.01 (0.71-1.44) | 0.93 (0.64-1.35) | 1.02 (0.70-1.48) | 0.93 (0.65-1.33) |
| Amount of warfarin use | ||||||
| ≤200 DDD | 63 | 1.85 (1.25-2.74) | 1.63 (1.10-2.42) | 1.15 (0.75-1.77) | 1.19 (0.78-1.80) | 1.06 (0.71-1.58) |
| 200-667 DDD | 32 | 0.65 (0.37-1.14) | 0.58 (0.33-1.01) | 0.68 (0.38-1.20) | 0.67 (0.36-1.25) | 0.64 (0.34-1.21) |
| >667 DDD | 26 | 0.72 (0.39-1.33) | 0.67 (0.36-1.23) | 0.83 (0.45-1.55) | 1.02 (0.56-1.87) | 0.87 (0.46-1.64) |
| Duration of warfarin use | ||||||
| ≤1 year | 56 | 1.52 (1.00-2.31) | 1.33 (0.88-2.02) | 1.00 (0.64-1.55) | 1.11 (0.73-1.68) | 0.97 (0.65-1.45) |
| 2-4 years | 44 | 0.96 (0.61-1.52) | 0.85 (0.54-1.34) | 0.88 (0.53-1.46) | 0.77 (0.44-1.35) | 0.78 (0.44-1.38) |
| 5 or more years | 21 | 0.71 (0.35-1.46) | 0.69 (0.34-1.40) | 0.84 (0.42-1.67) | 1.22 (0.64-2.33) | 1.02 (0.53-2.00) |
| Intensity of warfarin use | ||||||
| ≤128 DDD/year | 45 | 1.44 (0.93-2.24) | 1.25 (0.80-1.95) | 1.04 (0.66-1.64) | 1.20 (0.78-1.83) | 1.02 (0.68-1.53) |
| 128-200 DDD/year | 51 | 1.31 (0.85-2.01) | 1.16 (0.75-1.78) | 0.90 (0.54-1.49) | 0.82 (0.47-1.44) | 0.79 (0.45-1.40) |
| >200 DDD/year | 25 | 0.55 (0.29-1.05) | 0.51 (0.27-0.98) | 0.79 (0.43-1.44) | 0.86 (0.46-1.60) | 0.83 (0.44-1.57) |
Age-adjusted, multivariable-adjusted and lag-time hazard ratios (95% CI) related to all PCa deaths. Statistically significant results are bolded